Stromedix receives orphan drug designation for STX-100 in chronic allograft nephropathy
MORE (PDF) >
x
Stromedix profiled in Xconomy and In Vivo
Xconomy Article >
In Vivo Article >x
Stromedix raises $25 million in a Series B financing round
MORE (PDF) >x
Stromedix profiled in BioCentury in October, 2007
MORE (PDF) >
x
x
Corporate Factsheet
Download our Corporate Factsheet for information on who we are and what we do.
DOWNLOAD (PDF) >

 
Our lead program, STX-100, entered Phase 1 clinical testing in early 2008.

Stromedix is led by a team of seasoned biotechnology industry veterans with deep experience in drug development, and the company has developed a strong network of world-class clinical and scientific advisers.

Stromedix will focus initially on chronic indications but plans to leverage its expertise and expand its therapeutic pipeline into related settings such as acute organ failure and cancer.

The company is based in Cambridge, Massachusetts.

 

  
STX-100 is Stromedix’ first clinical candidate and is being developed for the treatment of chronic allograft dysfunction in kidney transplant recipients.

Humanized monoclonal antibody to integrin αvβ6
Entered phase 1 clinical testing in early 2008
In-licensed from Biogen Idec in 2007
Provides localized, injury-specific inhibition of TGF-β activation
Significant anti-fibrotic activity in preclinical models of lung, kidney and liver disease
Broad therapeutic utility in chronic organ failure, acute organ failure and cancer